USO DE BETA-LACTÁMICOS COMO ALTERNATIVA DEL TRATAMIENTO EMPÍRICO ACTUAL DE SEPSIS NEONATAL TARDÍA: REVISIÓN TEMÁTICA
Segovia Pizarro, Karen1; Segovia Colipe, Natalia1; Gálvez Ortega, Pablo1,2.
1 Licenciada/o en Obstetricia y Puericultura. Matrona/ón.
2 Profesor Asistente. Departamento de Promoción de la Salud de la Mujer y el Recién Nacido. Facultad de Medicina. Universidad de Chile.
Resumen |Abstract | Texto completo | Descargar cuerpo en pdf |
Objective: To analyze the use of beta-lactams in late- onset neonatal sepsis, compared with empirical treatment with vancomycin used currently, through the revision of scientific articles.
Methodology: Thematic review in LILACS and PubMed. The articles were selected by reading the title, abstract and full text. Searching criteria:
Human studies, articles by abstract and full text, in English and Spanish, and no more than 10 years since published.
Results: There is no relationship in duration or mortality in Sepsis when using beta-lactam, or using vancomycin. In addition, resistant strains to beta-lactam responded well in using beta-lactam as initial empirical therapy, without the need to resort to vancomycin, except in cases of non-clinical improvement.
Conclusions: Beta-lactams may be used as initial empirical therapy in late-onset neonatal sepsis as an alternative to current vancomycin therapy, restricting the use of vancomycin to resistance cases, or when there is no clinical improvement in the neonate, who is using a beta-lactam as a treatment.
Key words: Vancomycin, Beta-lactams, Sepsis, Newborn, Empiric, Therapy. |
